Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, Gao L, Zhang Q, Jia B, Hao L, Wang C, Zhang B.
Liu W, et al. Among authors: zhang l, zhang b, zhang q, zhang h.
Oncotarget. 2017 Jan 3;8(1):179-190. doi: 10.18632/oncotarget.10162.
Oncotarget. 2017.
PMID: 27329725
Free PMC article.